Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 2
1982 2
1983 1
1985 1
1988 6
1989 3
1990 3
1991 7
1992 8
1993 6
1994 7
1995 4
1996 9
1997 6
1998 4
1999 3
2000 12
2001 5
2002 4
2003 8
2004 8
2005 6
2006 5
2007 7
2008 5
2009 6
2010 5
2011 13
2012 7
2013 9
2014 13
2015 14
2016 14
2017 12
2018 7
2019 7
2020 8
2021 6
2022 9
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year

Filters applied: . Clear all
Page 1
Management of Pigmented Villonodular Synovitis (PVNS): an Orthopedic Surgeon's Perspective.
Bernthal NM, Ishmael CR, Burke ZDC. Bernthal NM, et al. Curr Oncol Rep. 2020 Jun 4;22(6):63. doi: 10.1007/s11912-020-00926-7. Curr Oncol Rep. 2020. PMID: 32494892 Review.
PURPOSE OF REVIEW: Pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumor (TGCT) encompasses a wide spectrum of disease and is divided into localized and diffuse variants. Surgical resection remains the pri …
PURPOSE OF REVIEW: Pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumor …
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Cannarile MA, et al. J Immunother Cancer. 2017 Jul 18;5(1):53. doi: 10.1186/s40425-017-0257-y. J Immunother Cancer. 2017. PMID: 28716061 Free PMC article. Review.
The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. ...The specificity of these agents and their potent blocking activity has been substantiated by impressive …
The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in thera …
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. Stacchiotti S, et al. Cancer Treat Rev. 2023 Jan;112:102491. doi: 10.1016/j.ctrv.2022.102491. Epub 2022 Dec 6. Cancer Treat Rev. 2023. PMID: 36502615 Free article. Review.
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. TGCT comprises a nodular- and a diffuse-type, with the former exhibiting mostly indolent course and …
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, …
Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
Staals EL, Ferrari S, Donati DM, Palmerini E. Staals EL, et al. Eur J Cancer. 2016 Aug;63:34-40. doi: 10.1016/j.ejca.2016.04.022. Epub 2016 Jun 5. Eur J Cancer. 2016. PMID: 27267143 Review.
At present, the optimal treatment strategy in patients with diffuse-type tenosynovial giant cell tumour (D-TGCT) is unclear. The purpose of this review was to describe current treatment options, and to highlight recent developments in the knowle …
At present, the optimal treatment strategy in patients with diffuse-type tenosynovial giant cell tumour ( …
Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA, Chawla PA. Alsayadi YMMA, et al. Anticancer Agents Med Chem. 2021;21(12):1510-1519. doi: 10.2174/1871520620999201102123555. Anticancer Agents Med Chem. 2021. PMID: 33143617 Review.
BACKGROUND: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the joints, which are characterized by pain, swelling, and limitation of movement of the joint. Surgery is the main treatment strategy, but the …
BACKGROUND: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the jo …
Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
Ravi V, Wang WL, Lewis VO. Ravi V, et al. Curr Opin Oncol. 2011 Jul;23(4):361-6. doi: 10.1097/CCO.0b013e328347e1e3. Curr Opin Oncol. 2011. PMID: 21577109 Review.
PURPOSE OF REVIEW: To review recent developments in the molecular pathogenesis of tenosynovial giant cell tumor (TGCT) or pigmented villonodular synovitis (PVNS) and its therapeutic implications. ...Recurrences occur in 8-20% of pa …
PURPOSE OF REVIEW: To review recent developments in the molecular pathogenesis of tenosynovial giant cell tumor …
Treatment updates on tenosynovial giant cell tumor.
Palmerini E, Staals EL. Palmerini E, et al. Curr Opin Oncol. 2022 Jul 1;34(4):322-327. doi: 10.1097/CCO.0000000000000853. Curr Opin Oncol. 2022. PMID: 35837703 Review.
PURPOSE OF REVIEW: Diffuse-type tenosynovial giant cell tumor (dt-TGCT) is a benign clonal neoplastic proliferation arising from the synovium. ...RECENT FINDINGS: TGCT cells overexpress colony-stimulating factor 1 (CSF1), resulting in rec …
PURPOSE OF REVIEW: Diffuse-type tenosynovial giant cell tumor (dt-TGCT) is a benign clonal neoplas …
Giant cell tumor of tendon sheath: study of 64 cases and review of literature.
Di Grazia S, Succi G, Fragetta F, Perrotta RE. Di Grazia S, et al. G Chir. 2013 May-Jun;34(5-6):149-52. doi: 10.11138/gchir/2013.34.5.149. G Chir. 2013. PMID: 23837951 Free PMC article. Review.
The giant cell tumor of tendon sheath (GCTTS) is the most common benign neoplasm in the hand after the ganglion cyst. ...Among the various possible factors that predispose to recurrence, it is necessary that the surgeon ensures complete excision of the tum …
The giant cell tumor of tendon sheath (GCTTS) is the most common benign neoplasm in the hand after the ganglion cyst. . …
Soft Tissue Pathology.
Shane AM, Reeves CL, Nguyen GB, Ferrise TD, Calaj PM. Shane AM, et al. Clin Podiatr Med Surg. 2023 Jul;40(3):381-395. doi: 10.1016/j.cpm.2023.02.003. Epub 2023 Apr 28. Clin Podiatr Med Surg. 2023. PMID: 37236677 Review.
Arthroscopy is frequently used to treat these soft tissue conditions such as instability, synovitis, impingement, arthrofibrosis, and other inflammatory disorders in the rearfoot and ankle. ...
Arthroscopy is frequently used to treat these soft tissue conditions such as instability, synovitis, impingement, arthrofibrosis, and …
Tenosynovial giant cell tumor: case report and review.
Lucas DR. Lucas DR. Arch Pathol Lab Med. 2012 Aug;136(8):901-6. doi: 10.5858/arpa.2012-0165-CR. Arch Pathol Lab Med. 2012. PMID: 22849738 Free article. Review.
They can be roughly divided into localized and diffuse types. Localized types include giant cell tumors of tendon sheath and localized pigmented villonodular synovitis, whereas diffuse types encompass conventional pigmented …
They can be roughly divided into localized and diffuse types. Localized types include giant cell tumors of tendon sheat …
250 results